

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent Application Publication

20250263730

Kind Code

A1

Publication Date

August 21, 2025

Inventor(s)

THOMPSON; Bradley G. et al.

COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID

Abstract

Embodiments of the present disclosure relate to a composition that comprises a recombinant plasmid (RP) with a sequence of nucleic acids. The sequence comprise a start region, an end region and an insert positioned between the start region and the end region. The insert encodes for a sequence of micro interfering ribonucleic acid (miRNA) that may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint protein.

Inventors: THOMPSON; Bradley G. (Calgary, CA), TOMPSON; Jillian (Calgary, CA)

Applicant: Wyvern Pharmaceuticals Inc. (Calgary, CA)

Family ID: 1000008586784

Appl. No.: 19/194571

Filed: April 30, 2025

Related U.S. Application Data

parent US continuation 18933750 20241031 PENDING child US 19194571

parent US division 18518177 20231122 PENDING child US 18933750

Publication Classification

Int. Cl.: C12N15/117 (20100101); C12N15/86 (20060101)

U.S. Cl.:

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATION [0001] The present application is a continuation of U.S. patent application Ser. No. 18/933,750 filed Oct. 31, 2024, entitled “Composition For Regulating Production Of Interfering Ribonucleic Acid” currently pending, which is a division of U.S. patent application Ser. No. 18/518,177 filed Nov. 22, 2023, entitled “Composition For Regulating Production Of Interfering Ribonucleic Acid” currently pending, the entirety of these are incorporated herein by reference.

SEQUENCE LISTING

[0002] This application contains a Sequence Listing electronically submitted via Patent Center to the United States Patent and Trademark Office as an XML Document file entitled “A8149361US-Sequence Listing.xml” created on 2023 Nov. 17 and having a size of 49,999 bytes. The information contained in the Sequence Listing is incorporated by reference herein.

TECHNICAL FIELD

[0003] The present disclosure generally relates to compositions for regulating production of interfering ribonucleic acid (RNA). In particular, the present disclosure relates to compositions for regulating gene expression and therefore, the production of interfering RNA, that will suppress checkpoint molecule overexpression or mis-expression.

BACKGROUND

[0004] Bioactive molecules, including checkpoint molecules, are necessary for the homeostatic control of biological systems.

[0005] When bioactive molecules are over-expressed or mis-expressed, homeostasis is lost, and disease is often the result.

[0006] As such, it may be desirable to establish therapies, treatments and/or interventions that address when homeostasis and regulation of bioactive molecules is lost to prevent or treat the resulting disease.

SUMMARY

[0007] Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint molecule. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint molecule such as PD-1. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint molecule such as PD-L1. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint molecule such as PD-L2. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint molecule such as CTLA4. In some embodiments of the present disclosure, the target biomolecule is an immune checkpoint molecule such as IDO1. In some embodiments of the present disclosure, the target biomolecule participates, directly or indirectly, in one or more immune responses. For example, the target biomolecule may be an immune checkpoint molecule that is a protein, a protein-protein complex—such as a receptor ligand pair—or other type of biomolecule that directly or indirectly inhibits an

immune response or that directly or indirectly stimulates an immune response.

[0008] In some embodiments of the present disclosure the compositions comprise a plasmid of deoxyribonucleic acid (DNA) that includes one or more insert sequences of nucleic acids that encode for the production of miRNA and a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated. Expression of the one or more insert sequences by one or more cells of the subject results in an increased production of the miRNA and, therefore, decreased translation or production of the target biomolecule by one or more of the subject's cells.

[0009] Some embodiments of the present disclosure relate to compositions that upregulate the production of miRNA that degrades, or causes degradation of, or inactivates or causes the inactivation of, the target mRNA of the target biomolecule.

[0010] Some embodiments of the present disclosure relate to a recombinant plasmid (RP). In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 2. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets mRNA of PD-1.

[0011] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 3. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets mRNA of PD-L1.

[0012] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 4. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets mRNA of PD-L2.

[0013] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 5. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets mRNA of CTLA4.

[0014] Some embodiments of the present disclosure relate to a recombinant plasmid. In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID NO. 1 and SEQ ID NO. 6. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets mRNA of IDO1.

[0015] Some embodiments of the present disclosure relate to a method of making a composition/target cell complex. The method comprising a step of administering a RP comprising SEQ ID NO. 1 and one of SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, or SEQ ID NO. 6, to a target cell for forming the composition/target cell complex, wherein the composition/target cell complex causes the target cell to increase production of one or more sequences of miRNA that decreases production of a target biomolecule.

[0016] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example PD-1. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of PD-1, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0017] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example PD-L1. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of PD-L1, which can be administered to a subject to increase the subject's production of one or more

sequences of the miRNA.

[0018] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example PD-L2. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of PD-L2, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0019] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example CTLA4. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of CTLA4, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

[0020] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example IDO1. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production of one or more sequences of miRNA, which are complete or partial sequences and/or combinations thereof, that target and silence the mRNA of IDO1, which can be administered to a subject to increase the subject's production of one or more sequences of the miRNA.

Description

DETAILED DESCRIPTION

[0021] Unless defined otherwise, all technical and scientific terms used therein have the meanings that would be commonly understood by one of skill in the art in the context of the present description. Although any methods and materials similar or equivalent to those described therein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned therein are incorporated therein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0022] As used therein, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, reference to “a composition” includes one or more compositions and reference to “a subject” or “the subject” includes one or more subjects.

[0023] As used therein, the terms “about” or “approximately” refer to within about 25%, preferably within about 20%, preferably within about 15%, preferably within about 10%, preferably within about 5% of a given value or range. It is understood that such a variation is always included in any given value provided therein, whether or not it is specifically referred to.

[0024] As used therein, the term “ameliorate” refers to improve and/or to make better and/or to make more satisfactory.

[0025] As used therein, the term “cell” refers to a single cell as well as a plurality of cells or a population of the same cell type or different cell types. Administering a composition to a cell includes in vivo, in vitro and ex vivo administrations and/or combinations thereof.

[0026] As used therein, the term “complex” refers to an association, either direct or indirect, between one or more particles of a composition and one or more target cells. This association results in a change in the metabolism of the target cell. As used therein, the phrase “change in metabolism” refers to an increase or a decrease in the one or more target cells' production of one or

more proteins, and/or any post-translational modifications of one or more proteins.

[0027] As used therein, the term “composition” refers to a substance that, when administered to a subject, causes one or more chemical reactions and/or one or more physical reactions and/or one or more physiological reactions and/or one or more immunological reactions in the subject. In some embodiments of the present disclosure, the composition is a plasmid vector.

[0028] As used therein, the term “endogenous” refers to the production and/or modification of a molecule that originates within a subject.

[0029] As used therein, the term “exogenous” refers to a molecule that is within a subject but that did not originate within the subject. As used therein, the terms “production”, “producing” and “produce” refer to the synthesis and/or replication of DNA, the transcription of one or more sequences of RNA, the translation of one or more amino acid sequences, the post-translational modifications of an amino acid sequence, and/or the production of one or more regulatory molecules that can influence the production and/or functionality of an effector molecule or an effector cell. For clarity, “production” is also used therein to refer to the functionality of a regulatory molecule, unless the context reasonably indicates otherwise.

[0030] As used therein, the term “subject” refers to any therapeutic target that receives the composition. The subject can be a vertebrate, for example, a mammal including a human. The term “subject” does not denote a particular age or sex. The term “subject” also refers to one or more cells of an organism, an in vitro culture of one or more tissue types, an in vitro culture of one or more cell types, ex vivo preparations, and/or a sample of biological materials such as tissue, and/or biological fluids.

[0031] As used therein, the term “target biomolecule” refers to a checkpoint molecule that is found within a subject. A biomolecule may be endogenous or exogenous to a subject and when bioavailable the biomolecule may inhibit or stimulate an immune process within the subject.

[0032] As used therein, the term “target cell” refers to one or more cells and/or cell types that are deleteriously affected, either directly or indirectly, by a dysregulated biomolecule. The term “target cell” also refers to cells that are not deleteriously affected but that are the cells in which it is desired that the composition interacts.

[0033] As used therein, the term “therapeutically effective amount” refers to the amount of the composition used that is of sufficient quantity to ameliorate, treat and/or inhibit one or more of a disease, disorder or a symptom thereof. The “therapeutically effective amount” will vary depending on the composition used, the route of administration of the composition and the severity of the disease, disorder or symptom thereof. The subject's age, weight and genetic make-up may also influence the amount of the composition that will be a therapeutically effective amount.

[0034] As used therein, the terms “treat”, “treatment” and “treating” refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing an occurrence of a disease, disorder or symptom thereof and/or the effect may be therapeutic in providing a partial or complete amelioration or inhibition of a disease, disorder, or symptom thereof. Additionally, the term “treatment” refers to any treatment of a disease, disorder, or symptom thereof in a subject and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) ameliorating the disease.

[0035] As used therein, the terms “unit dosage form” and “unit dose” refer to a physically discrete unit that is suitable as a unitary dose for patients. Each unit contains a predetermined quantity of the composition and optionally, one or more suitable pharmaceutically acceptable carriers, one or more excipients, one or more additional active ingredients, or combinations thereof. The amount of composition within each unit is a therapeutically effective amount.

[0036] Where a range of values is provided therein, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is

encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also, encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0037] In some embodiments of the present disclosure, a composition is a recombinant plasmid (RP) for introducing genetic material, such as one or more nucleotide sequences, into a target cell for reproduction or transcription of an insert that comprises one or more nucleotide sequences that are carried within the RP. In some embodiments of the present disclosure, the RP is delivered without a carrier, by a viral vector, by a protein coat, or by a lipid vesicle. In some embodiments of the present disclosure, the vector is an adeno-associated virus vector.

[0038] In some embodiments of the present disclosure, the insert comprises one or more nucleotide sequences that encode for production of at least one sequence of miRNA that decreases the production of target biomolecules. The miRNA may, directly or indirectly, bind to and degrade the target mRNA or otherwise inactivate the target mRNA so that less or none of the target-biomolecule protein is produced.

[0039] In some embodiments of the present disclosure, the target biomolecule is PD-1.

[0040] In some embodiments of the present disclosure, the target biomolecule is PD-L1.

[0041] In some embodiments of the present disclosure, the target biomolecule is PD-L2.

[0042] In some embodiments of the present disclosure, the target biomolecule is CTLA4.

[0043] In some embodiments of the present disclosure, the target biomolecule is IDO1.

[0044] In some embodiments of the present disclosure, the insert comprises one or more nucleotide sequences that each encode one or more miRNA sequences that may be complimentary to and degrade, or cause degradation of, mRNA of the target biomolecule.

[0045] Some embodiments of the present disclosure relate to a composition that can be administered to a subject with a condition that results, directly or indirectly, from the production of a dysregulated biomolecule. When a therapeutically effective amount of the composition is administered to the subject, the subject may change production and/or functionality of one or more biomolecules.

[0046] In some embodiments of the present disclosure, the subject may respond to receiving the therapeutic amount of the composition by changing production and/or functionality of one or more intermediary molecules by changing production of one or more DNA sequences, one or more RNA sequences, and/or one or more proteins that regulate the levels and/or functionality of the one or more intermediary molecules. The one or more intermediary molecules regulate the subject's levels and/or functionality of the one or more biomolecules.

[0047] In some embodiments of the present disclosure, administering a therapeutic amount of the composition to a subject upregulates the production, functionality or both one or more sequences of miRNA that each target the mRNA of one or more target biomolecules. In some embodiments of the present disclosure, there are one, two, three, four, five, or six miRNA sequences that each are complimentary to and degrade, or cause degradation of, one biomolecule, such as PD-1, PD-L1, PD-L2, CTLA4, or IDO1. In some embodiments of the present disclosure, the composition may comprise multiple copies of the same nucleotide sequence of miRNA.

[0048] In some embodiments of the present disclosure, the composition is an RP that may be used for gene therapy. The gene therapy is useful for increasing the subject's endogenous production of one or more sequences of miRNA that target the mRNA of a target biomolecule. For example, the RP can contain one or more nucleotide sequences that cause increased production of one or more nucleotide sequences that cause an increased production of one or more miRNA sequences that are each complimentary to and degrade, or cause degradation of, or inactivate, or cause inactivation of, one biomolecule, such as PD-1, PD-L1, PD-L2, CTLA4, or IDO1.

[0049] In some embodiments of the present disclosure, the delivery vehicle of the RP used for gene

therapy may be a virus that can be enveloped, or not (unenveloped), replication effective or not (replication ineffective), or combinations thereof. In some embodiments of the present disclosure, the vector is a virus that is not enveloped and not replication effective. In some embodiments of the present disclosure, the vector is a virus of the Parvoviridae family. In some embodiments of the present disclosure, the vector is a virus of the genus *Dependoparvovirus*. In some embodiments of the present disclosure, the vector is an adeno-associated virus (AAV). In some embodiments of the present disclosure, the vector is a recombinant AAV. In some embodiments of the present disclosure, the vector is a recombinant AAV6.2FF.

[0050] In some embodiments of the present disclosure, the delivery vehicle of the RP used for gene therapy may be a protein coat.

[0051] In some embodiments of the present disclosure, the delivery vehicle of the RP used for gene therapy may be a lipid vesicle.

[0052] The embodiments of the present disclosure also relate to administering a therapeutically effective amount of the composition. In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to a patient is between about 10 and about 1×10^{16} TCID₅₀/kg (50% tissue culture infective dose per kilogram of the patient's body mass). In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to the patient is about 1×10^{13} TCID₅₀/kg. In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to a patient is measured in TPC/kg (total particle count of the composition per kilogram of the patient's body mass). In some embodiments the therapeutically effective amount of the composition is between about 10 and about 1×10^{16} TCP/kg.

[0053] Some embodiments of the present disclosure relate to an adenovirus associated virus (AAV) genome consisting of a RP that when operable inside a target cell will cause the target cell to produce a miRNA sequence that downregulates production of a biomolecule, with examples being PD-1, PD-L1, PD-L2, CTLA4, or IDO1. The RP is comprised of AAV2 inverted terminal repeats (ITRs), a composite CASI promoter, a human growth hormone (HGH) signal peptide followed by a miRNA expression cassette containing up to six different miRNAs targeting PD-1, PD-L1, PD-L2, CTLA4, or IDO1, followed by a Woodchuck Hepatitis Virus post-transcriptional regulatory element (WPRE) and an SV40 polyA signal.

TABLE-US-00001 SEQ ID NO. 1 (backbone sequence No. 1): 5'

aatcaacctctggattacaaaattgtgaaagattgactgggtattcttaactatgttgctcctttacgctatgtggatacgtgctttaatgcctttgt
atcatgctattgcttcccgatggctttcatttctcctgtataaatcctgggtgctgtctttatgaggagttgtggccggtgtcaggcaac
gtggcgtggtgtgactgtgtttgctgacgcaacccccactgggtggggcattgccaccacctgtcagctccttccgggacttccgcttccc
cctccctattgccacggcggaactcatcgccgctgccttgcccgcgtgctggacaggggctcggctgttgggcactgacaattccgtggtgt
tgtcggggaaatcatcgtccttccctggctgctcgctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctc
aatccagcggaccttccctcccgccgctgctgcccgcctctgcggcctctccgcgtcttcgccttcgcctcagacgagtcggatctccctt
gggcccgcctccccgcctaagcttatcgataccgtcgagatctaactgtttattgcagcttataatggttacaataaagcaatagcatcaca
ttcacaaataaagcatttttctactgcatttagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatctcgacctgactagagc
atggctacgtagataagtagcatggcgggtaatacctaactacaaggaacccctagtgatggagttggccactccctctctgcgcgctcgt
cgctcactgaggccgggacgacaaaggtcgcccgacgcccgggctttgccggggcgccctcagtgagcgagcgagcgcgagctgg
cgtaatagcgaagaggcccgacccgatcgccctcccaacagttgcgcagcctgaatggcgaatggcgattccgttgcaatggctggcgg
taatattgttctggatattaccagcaaggccgatagtttagtttctactcaggcaagtgtattactaatcaagaagtattgcgacaac
ggtaatttgcgtgatggacagactctttactcggtggcctcactgattataaaaacacttctcaggattctggcgtagcgttctgtaaaatc
ccttaatcggcctcctgttttagctcccgcctctgattctaacgaggaaagcacgttatacgtgctcgtcaaagcaaccatagtagcgccctgt
agcggcgcatgaagcgcgggggtgtggtgttacgcgcagcgtgaccgctacacttgccagcgccctagcgccccgctccttgcgttctt
cccttcttctcgccacgttcgcccgttccccgtcaagctctaaatcgggggctcccttaggggtccgatttagtgctttacggcacctcga
ccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggttttcgcccttgacgttgagtcacgttcttta
atagtggactctgttccaaactggaacaacactcaaccctatctcggctctattcttttgattataagggtatttgcgatttcggcctattgggtta

aaaatgagctgatttaacaaaaatttaacgcgaattttaacaaatatttgcttatacaaatcttctggttttggggct
tttctgattatcaaccgggtacatatgattgacatgctagttttacgattaccgttcacgattctcttgtttgctccagactctcaggcaatgacct
gatagcctttgtagagacctctcaaaaatagctaccctctccggcatgaatttatcagctagaacgggtgaatatcatattgatgggtgattgact
gtctccggcctttctcaccggttgaatctttacctacacattactcaggcattgcatttaaaatataatgaggggtctaaaaattttatccttgcggtg
aaataaaggcttctcccgcaaaagtattacaggggtcataatgttttgggtacaaccgatttagctttatgctctgaggctttattgcttaattttgcta
attctttgcttgctgtatgattattggatgttgggaattcctgatgcgggtattttctccttacgcatctgtgcgggtatttcacaccgcatatgggtgca
ctctcagtacaatctgctctgatgccgcatagttaagccagccccgacaccgccaacaccgctgacgcgcctgacgggcttgctgctc
ccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagagggtttaccgtcatcaccgaaacgcgcgagacgaa
agggcctcgtgatacgcctatttttatagggttaattgtcatgataataatggtttcttagacgtcagggtggcacttttcggggaaatgtgcgcggaa
cccctatttgttttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttaataattgaaaaaggaagagt
atgagtattcaacatttccgtgtcgccttattccctttttgcggtatttgccttctgttttgtcaccagaaaacgctgggtgaaagtaaaagat
gctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagtttgcggccgaagaacgtttt
ccaatgatgagcacttttaaaagtctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcgggtcgccgcatacactatt
ctcagaatgacttgggtgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgtgccataacca
tgagtataactgctgcggccaacttacttctgacaacgatcggaggaccgaaggagtaaccgctttttgcacaacatgggggatcatgta
actcgccttgatcgttgggaaccgggagctgaatgaagccatacacaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacg
ttgcgcaaaactattaactggcgaactacttacttagcttcccggcaacaattaatagactggatggaggcggataaagtgcaggaccactt
ctgcgctcggcccttccggctgggtgtttattgctgataaatctggagccgggtgagcgtgggtctcgcggtatcattgcagcactggggcc
agatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgtgagataggt
gcctcactgattaagcattggtaactgtcagaccaagttactcatatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtg
aagatccttttgataatctcatgacaaaatcccttaacgtgagtttctgtccactgagcgtcagaccccgtagaaaagatcaaaggatcttct
tgagatccttttttctgcgcgtaatctgctgcttgcacaacaaaaaaccaccgctaccagcgggtgggttgttgcgggatcaagagctaccaac
tcttttccgaaggttaactggcttcagcagagcgcagatacacaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctg
tagcaccgcctacatacctcgtctgctaactcctgttaccagtggctgctgccagtggcgataagtcgtgttaccgggttgactcaagac
gatagttaccggataaggcgagcgggtcgggctgaacgggggggttcgtgcacacagcccagcttgagcgaacgacctacaccgaact
gagatacctacagcgtgagctatgagaaagcgccacgctcccgaaggagaaaggcggacaggtatccggtaagcggcagggtcgg
aacaggagagcgcacgaggagcttccagggggaaacgcctgggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgat
ttttgtgatgctcgtcagggggggcggagcctatggaaaaacgccagcaacgcggcctttttacgggtcctggccttttgccttttgcctca
catgttcttctcgttatccctgattctgtggataaccgtattaccgcctttgagtgagctgataaccgctcgccgcagccgaacgaccgag
cgcagcagtgagtgagcaggaagcgggaagagcgcccaatacgcacaaccgcctctccccgcgcgttggccgattcattaatgcagca
gctgcgcgctcgtcgtcactgaggccgcccgggcaaagcccggggtcgggcgacctttgggtcgcccgccctcagtgcagcagcga
gcgcgcagagaggagtgggcaactccatcactaggggttcctttagttaatgattaaccgcctatgctacttatctacgtagccatgctct
aggacattgattattgactagtggagtccgcgttacataacttacggtaaatggcccgcctgggtgaccgcccacgacccccgcccattg
acgtcaataatgacgtatgttcccatagtaacgccaataggagcatttccattgacgtcaatgggtggagtatttacggtaaaactgccacttgg
cagtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaatggcccgctggcattatgccagtagatgacctt
atgggactttcctacttggcagtagatctacgtattagtcacgtattaccatgggtcaggtgagccccacgttctgcttactctccccatctc
ccccccctccccaccccccaattttgtattatttttttaattttttgtgcagcgtatggggggcgggggggggggggggggcgcgcgccaggc
ggggcgggggcgggggcgagggggcgggggcgggggcgagggcgagaggtgcggcgggcagccaatcagagcggcgcgctccgaaagt
ccttttatggcgaggcgggcgggcgggcgccctataaaaagcgaagcgcgcggcgggcggggagtcgctgcgcgctgccttcgcccc
gtgccccgctccgcccgcctcgcgcggccccggcctctgactgaccgcgttactaaaacaggtaagtccggcctccgcgcgggg
tttggcgctcccgcgggcgccccctcctcacggcgagcgtgccacgtcagacgaaggcgagcgcgctctgatccttccgcc
cggacgctcaggacagcggccccgctgctcataagactcggccttagaaccacagtagatcagcagaaggacattttaggacgggacttgggt
gactctagggcactgggttttcttccagagagcggaaacaggcgagggaaaagtagtcccttctcggcgattctgcggagggtatcctggtg
gcgggtgaacccgatgatgccttactaaccatgttcatgttttcttttttctacaggtcctgggtgacgaacagggtaccgccaccatggc
caccggctctcgcacaagcctgctgctggcttccgactgctgtgcctgcttgggtccaggagggtccgcc 3' SEQ ID

NO. 2 (miRNA expression cassette No. 2—PD-1): 5'

gctagcatcgaaccgtcgctatgtgctggaggcttgcgaaggctgtatgctgtacctaaagaactgcatcctggccgttttggcctctgactg
acggccaggatggttcttaggtacaggacacaaggcctgttactagcactcacatggaacaaatggccttagcctggaggcttgcgaag
gctgtatgctgtcgtaaagccaatagggttagtcccgttttggcctctgactgacgggactaaccttggccttacgacaggacacaaggcctgt
actagcactcacatggaacaaatggccttagcctggaggcttgcgaaggctgtatgctgagagagaccgcaaataccggacgggtttg

gcctctgactgacgcctctgtaatgcggctctctcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3'
SEQ ID NO. 3 (miRNA expression cassette No. 3—PD-L1): 5'
gctagcatcgataccgtcgctatgtgctggaggcttgctgaaggctgtatgctgagagacttacttgtatgctgcgttttggcctctgactga
cgagcatctaagtaagtctctcaggacacaaggcctgttactagcactcacatggaacaaatggcctctagcctggaggcttgctgaaggc
tgtatgctgactattcatcactctcaccgcttttggcctctgactgacgggtgagagtgtgaaatagtcaggacacaaggcctgttactag
cactcacatggaacaaatggcctctagcctggaggcttgctgaaggctgtatgctgatatgaatgacaatcacagccgagtttggcctctga
ctgacgtggctgtgagtcattcatatcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3' SEQ
ID NO. 4 (miRNA expression cassette No. 4—PD-L2): 5'
gctagcatcgataccgtcgctatgtgctggaggcttgctgaaggctgtatgctgacaatcaacattggcagtagctcgtttggcctctgactg
acgagctactgcatgttgattgtcaggacacaaggcctgttactagcactcacatggaacaaatggcctctagcctggaggcttgctgaagg
ctgtatgctgaataagcctttatccatagtcccgcttttggcctctgactgacgggactatggaaaggctattcaggacacaaggcctgttacta
gcactcacatggaacaaatggcctctagcctggaggcttgctgaaggctgtatgctgacaactgtctcaaattactgctcgtttggcctctga
ctgacgagcagtaatgagacagttgtcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3' SEQ
ID NO. 5 (miRNA expression cassette No. 5—CTLA4): 5'
gctagcatcgataccgtcgctatgtgctggaggcttgctgaaggctgtatgctgtcactcaccttgtgcagaagacgttttggcctctgactg
acgtctctgcaaagggtgagtgcaggacacaaggcctgttactagcactcacatggaacaaatggcctctagcctggaggcttgctgaag
gctgtatgctggttcttagcctatctcaagtagcgcttttggcctctgactgacgctacttgagaggctaagacacaggacacaaggcctgttac
tagcactcacatggaacaaatggcctctagcctggaggcttgctgaaggctgtatgctggtctatgtctaaattccagcagcgcttttggcctct
gactgacgctgctggaatagacatgacacaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3'
SEQ ID NO. 6 (miRNA expression cassette No. 6—IDO1): 5'
gctagcatcgataccgtcgctatgtgctggaggcttgctgaaggctgtatgctgtcacttgaattgcttaccgctccgcttttggcctctgactg
acggagcggtaagattcaagtgcaggacacaaggcctgttactagcactcacatggaacaaatggcctctagcctggaggcttgctga
aggctgtatgctgtgtctgacatctcaagtagcgcttttggcctctgactgacgctacttgagaggctaagacacaggacacaaggcctgtt
actagcactcacatggaacaaatggcctctagcctggaggcttgctgaaggctgtatgctgatgtttccgggaaacagtgactcgcttttggcc
tctgactgacgattcactgtcccggaaacatcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3'
SEQ ID NO: 7 = SEQ ID NO: 1 + SEQ ID NO: 2 5'
aatcaacctctggattacaaaatttgtgaaagattgactgggtattcttaactatgttgctccttttacgctatgtggatacgtgctttaatgcctttgt
atcatgctattgcttcccgtatggctttcattttctcctctgtataaatcctggttgctgtctctttatgaggagttgtggcccggtgtcaggcaac
gtggcggtggtgtgactgttttgcgacgcaacccccactgggtggggcattgccaccacctgtcagctcctttccgggactttcgctttccc
cctccctattgccacggcggaactcatcgccgctgccttgcccgtgctggacaggggctcggctgttgggactgacaattccgtggtgt
tgtcgggggaaatcatcgcttttcccttggtgctgcgctgtgttgcacctggattctgcgcgggacgtccttctgctacgtcccttcggccctc
aatccagcggaccttccctcccgcggtgctgcggctctgcggccttccgcgtcttcgcttcgacctcagacgagtcggatctccctt
gggcccgcctccccgcctaagcttatcgataccgtcgagatctaactgtttattgcagcttataatggttacaataaagcaatagcatcacaaa
tttcacaaataaagcattttttactgcattctagtgtgtgttgcctaaactcatcaatgtatcttatcatgtctggatctcgacctcgactagagc
atggctacgtagataagtagcatggcggttaataactacaaggaacccctagtgtatggagttggccactccctctctgcgcgctcgt
cgctcactgaggccgggacacaaaggctgcccgcgcccgggcttggccgggagcagtgagcagcagcgcgcagctgg
cgtaatagcgaagaggcccgaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgattccgttgcaatggctggcgg
taatattgttctggatattaccagcaaggccgatagttgagttcttactcaggcaagtgtattactaatcaagaagtattgcgacaac
gggttaatttgcgtgatggacagactctttactcgggtggcctcactgattataaaaacacttctcaggattctggcgtaaccgttctgtctaaaatc
ccttaatcggcctcctgttttagtccccgctctgattctaacgaggaaaagcacgttatacgtgctcgtcaaagcaaccatagtagcgccctgt
agcggcgcatataagcgcggcggtgtgtgtgttacgcgcagcgtgaccgtacacttgccagcgccttagcgccccgctcctttcgctttctt
cccttcccttctcgccacgttcgcccgtttccccgtaagctctaaatcgggggctcccttaggggtccgatttagtgctttacggcacctcga
ccccaaaaaacttgattaggggtgatgggtcacgtatgggcatcgccctgatagacggttttcgcccttgacgttgagtcacgttcttta
atagtggactctgttccaaactggaacaacactcaaccctatctcggtctattcttttgattataaagggttttgcgatttcggcctattgggtta
aaaatgagctgatttaacaaaaatttaacgcgaatttaacaaaaatattaacgtttacaatttaaatatttgctatacaatcttctgttttggggct
tttctgattatcaaccggggtacatatgattgacatgctagttttacgattaccgttcacgtattcttctgttctccagactctcaggcaatgacct
gatagcctttgtagagaccttcaaaaatagctaccctctccggcatgaatttatcagctagaacgggtgaatatcatattgatgggtgattgact
gtctccggcctttctcaccggttgaatctttactacacattactcaggcattgcattaaaaatataggggttctaaaaattttatccttgcgttg
aaataaaggcttctcccgcaaaagtattacagggtcataatgttttgggtacaaccgatttagctttatgctctgaggcttattgcttaattttgcta
attctttgccttgctgtatgattattggatgttgggaattcctgatgcgggtattttctccttacgcatctgtgcgggtatttcacaccgcatatgggtga

ctctcagataaatctgctctgatgccgcatagttaagccagccccgacaccccgccaacacccgctgacgcgcctgacgggctgtctgctc
ccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagagggtttaccggtcatcaccgaaacgcgcgagacgaa
agggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaa
cccctatttgtttattttctaataacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataattgaaaaaggaagagt
atgagtattcaacatttccgtgtcgccttattccctttttgcggcattttgccttctgtttttgtcaccagaaaacgctgggtgaaagtaaaagat
gctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgcggcgaagaacgtttt
ccaatgatgagcacttttaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactatt
ctcagaatgacttgggtgagtactaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgtcgcataacca
tgagtataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgctttttgcacaacatgggggatcatgta
actcgccttgatcgttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacg
ttgcgcaaaactattaactggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcgggataaagtgcaggaccactt
ctgcgctcggcccttccggctggctgtgtttattgtgataaatctggagccgggtgagcgtgggtctcgcggtatcattgcagcactggggcc
agatggtaagccctcccgtatcgtagtattctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgtgagataggt
gcctcactgattaagcattggtaactgtcagaccaagttactcatatatactttagattgatttaaaacttcatttttaattaaaaaggatctaggtg
aagatccttttgataatctcatgacaaaatcccttaacgtgagtttcttccactgagcgtcagacccccgtagaaaagatcaaaggatcttct
tgagatccttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcgggtggtttgtttgccggatcaagagctaccaac
tcttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagtaggcccaccacttcaagaactctg
tagcaccgcctacatacctcgtctgctaactctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccggggttgactcaagac
gatagttaccggataaggcgcagcggctcgggctgaacgggggggttctgtcacacagcccagcttgagcgaacgacctacaccgaact
gagatacctacagcgtgagctatgagaaagcgccacgcttcccgaaggagaaaggcggacaggtatccggtaagcggcagggtcgg
aacaggagagcgcacgaggggagcttccaggggggaaacgcctggtatctttatagtcctgtcgggtttccacacttgacttgagcgtcgtat
tttgtgatgctcgtcagggggggcggagcctatggaaaaacgccagcaacgcggcctttttacgggtcctggccttttctggtgcttttctca
catgttcttctcgttattccctgattctgtggataaccgtattaccgcctttgagttagctgataccgctcgcgcagccgaacgaccgag
cgcagcgtcgtcgtcgtcactgaggccgcccgggcaaagccccgggctcgggacgacctttggctcggcggcctcagtgagcgtgagcga
gctgcgcgagagagggtggccaactccatcactaggggttctttagttaatgattaaccgccatgctacttattctacgtagccatgctct
aggacattgattattgactagtggagtccgcgttacataacttacggtaaatggcccgctggctgaccgcccacgacccccgcccattg
acgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtattttacggtaaaactgcccacttgg
cagtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaatggcccgctggcattatgccagtagatgacctt
atgggactttcctacttggcagtagatctacgtattagtcacgtattaccatggctcaggtgagccccacgttctgcttacttctccccatctc
ccccccctccccaccccccaattttgtattatttttttaattttttgtgcagcgtatggggggcggggggggggggggggggcgcgccaggc
ggggcgggggcgggggcgagggggcggggcgggggcgagggcgagaggtgcggcgagccaatcagagcggcgcgctccgaaagt
ccttttatggcgaggcggcgggcgggcgggccctataaaaaagcgaagcgcgcggcgggcggggagtcgctgcgcgctgccttcgcccc
gtgccccgctccgcccgcctcgcgcggccccggcctctgactgaccgcgttactaaaacaggtaagtccggcctccgcgcgggg
tttggcgctcccgcgggcgccccctctcacggcgagcgtgccacgtcagacgaaggcgagcgtcgtcgtatccttccgcc
cggacgctcaggacagcggcccgtgctcataagactcggccttagaaccacagtagatcagcagaaggacatttttaggacgggacttgggt
gactctagggcactggttttcttccagagagcggaaacaggcgagggaaaagtagtccttctcggcgattctgcggagggatctccgtggg
gcgggtgaacgccgatgatgccttactaaccatgttcatgttttcttttttctacaggctcctgggtgacgaacagggtaccgccaccatggc
caccggctctcgcacaagcctgctgctggcttccggactgctgtgccttggctccaggagggtccgcccgtagcatcgataccgtc
gctatgtgctggaggctgctgaaggctgtatgctgtacctaagaactgcacccctggccgttttggcctctgactgacggccaggatgggtctt
aggtagaggacacaaggcctgttactagcactcacatggaacaaatggcctctagcctggaggcttgcgaaggctgtatgctgtcgttaaag
ccaatagggttagtcccgttttggcctctgactgacgggactaaccttggctttacgacaggacacaaggcctgttactagcactcacatggaa
caaatggcctctagcctggaggcttgcgaaggctgtatgctgagagagaccgcaaattaccggacgggttttggcctctgactgaccgtcct
gtaatcggtctctctcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3' SEQ ID NO:
8 = SEQ ID NO: 1 + SEQ ID NO: 3 5'

aatcaacctctggattacaaaatttgtgaaagattgactgggtattcttaactatgttgcctcttttacgctatgtggatacgtgctttaatgcctttgt
atcatgctattgcttcccgtatggctttcattttctcctctgtataaatcctggttgcgtctctttatgaggagttgtggccgttgcaggcaac
gtggcgtggtgtgactgtgttgcgtgacgcaacccccactgggtggggcattgccaccacctgtcagctccttccgggacttccgttccc
cctccctattgccacggcggaactcatcgccgcctgccttggccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgt
tgtcgggggaaatcatcgtccttcttggctgctcgcctgtgttgcacctggattctgcgcgggacgtccttctgctacgtcccttcggccctc

aatccagcggaccttctcccgcgccgtctgcggccttccgcgtcttcgccttcgacctcagacgagtcggatctccctt
gggcccgcctccccgcctaagcttatcgataccgtcgagatctaacttggtattgacgttataatggttacaaataaagcaatagcatcaciaa
tttcacaaataaagcatttttttactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatctcgacctcgactagagc
atggctacgtagataagtagcatggcggttaatcattaactacaaggaacccctagtgatggagttggccactccctctctgcgcgctcgct
cgctcactgagggccggcgaccaaaggtcgccgacgcccgggctttgcccggggcgccctcagtgagcgagcgagcgcgagctgg
cgtaatagcgaagaggcccgacccgatcgcccttcccaacagttgcgcgagcctgaatggcgaatggcgattccgttgcaatggctggcgg
taatattgttctggatattaccagcaaggccgatagtttgagttcttactcaggcaagtgtattactaatcaaagaagtattgcgacaac
ggtaatttgcgtgatggacagactctttactcgggtggcctcactgattataaaaacacttctcaggattctggcgtaccgttctgtctaaaac
ccttaatcggcctcctgtttagctcccgcctctgattctaacgaggaaaagcacgttatacgtgctcgtaaaagcaaccatagtacgcgcctgt
agcggcgcattaagcgcgggcggtgtggtgttacgcgcagcgtgaccgtacacttgccagcgccctagcgcccgctccttcgctttctt
ccctcctttctcgccacgttcgcccggcttccccgtcaagctctaaatcgggggctcccttaggggtccgatttagtgctttacggcacctcga
ccccaaaaaacttgattaggggtgatggtcacgtagtgggccatcgccctgatagacggttttgcctttgacgttgagtcacgttcttta
atagtggactctgttccaaactggaacaacactcaaccctatctcggtctattcttttgattataagggatttggcgatttcggcctattggtaa
aaaatgagctgatttaacaaaaattaacgcgaatttaacaaaaatattaacgtttacaattaaatatttgctatacaatcttctgttttggggct
tttctgattatcaaccggggtacatatgattgacatgctagtttacgattaccgttcacgtattctgtttgctccagactctcaggcaatgacct
gatagcctttgtagagacctctcaaaaatagctaccctctccggcatgaatttatcagctagaacggttgaaatcatattgatgggtgattgact
gtctccggcctttctcacccgttgaatctttacacatactcaggcattgcatttaaaatataaggggttctaaaaattttatccttgcggtg
aaataaaggcttctcccgcaaaagtattacaggggtcataatgttttggtaaacgatttagctttagctctgaggcttattgcttaattttgcta
attctttgccttgctgtatgatttattggatgttgggaattctgatgcggtattttctcttacgcatctgtgcggtatttcacaccgcatatgggtga
ctctcagtacaatctgctctgatgccgcatagttaagccagccccgacaccgccaacaccgctgacgcgcctgacgggcttgctgctc
ccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagagggtttaccgtcatcaccgaaacgcgcgagacgaa
agggcctcgtgatacgcctattttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaa
cccctatttgttttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataattgaaaaaggaagagt
atgagtattcaacatttcggtgctgccttattcccttttgcggcattttgccttctgttttgcctaccagaaaacgctggtgaaagtaaaagat
gctgaagatcagttgggtgcacgagtggttcatcgaactggatctcaacagcggtaagatccttgagagtttgcggccgaagaacgtttt
ccaatgatgagcacttttaaaagtctgctatgtggcgcggtattatcccgattgacgccgggcaagagcaactcggtcgccgcatacactatt
ctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgtgccataacca
tgagtataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagtaaccgctttttgcacaacatgggggatcatgta
actcgcttgatcggtgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacg
ttgcgcaaaactattaactggcgaactacttactctagcttcccggaacaattaatagactggatggaggcggtataaagtgcaggaccactt
ctgcgctcggcccttccggctggctggttattgctgataaatctggagccgggtgagcgtgggtctcgcggtatcattgcagcactggggcc
agatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggt
gcctcactgattaagcatttgtaactgtcagaccaagtttactcataataacttttagattgatttaaaacttcatttttaattaaaaggatctaggtg
aagatccttttgataatctcatgacaaaatcccttaacgtgagtttctgcttccactgagcgtcagaccccgtagaaaagatcaaaggatcttct
tgagatccttttttctgcgcgtaatctgctgcttgcaaaacaaaaaaccaccgctaccagcgggtggtttgttgcgggatcaagagctaccaac
tcttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctg
tagcaccgcctacatacctcgtctgctaactctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttgactcaagac
gatagttaccggataaggcgagcggtcggtggaacggggggttctgtcacacagcccagcttgagcgaacgacctacaccgaact
gagatacctacagcgtgagctatgagaaagcgccacgcttcccgaaggggagaaaggcgagcaggtatccggtaagcggcaggggtcgg
aacaggagagcgcacgaggagcttccaggggggaaacgcctggtatctttatagtcctgtcggggttccacacttgacttgagcgtcgat
tttgtgatgctcgtcagggggggcgagcctatggaaaaacgccagcaacgcggcctttttacgggtcctggccttttgcgtggccttttgc
catgttcttctcgttatccctgattctgtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgag
cgagcgcgagtcagtgcgaggaagcggaagagcgcccaatacgcgaacccgcttccccgcgcgttggccgattcattaatgcagca
gctgcgcgctcgtcgtcactgaggccgcccgggcaaagcccgggctcgggcgacctttggtcgcccgccctcagtgagcgcgagcga
gcgcgcagagaggagtggtccaaactccatcactaggggttctttagttaatgattaaccgcatgctacttatctacgtagccatgctct
aggacattgattattgactagtggagtccgcgttacataacttacggtaaatggcccgcctggctgaccgccaacgacccccgcccattg
acgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaaactgcccacttgg
cagtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaatggcccgctggcattatgccagtagatgacctt
atgggactttctacttggcagtagatctacgtattagtcacgtattaccatggctcaggtgagccccacgttctgcttactctccccatctc
ccccctccccaccccccaatttgtatttatttttaatttttgtgcagcgtggggggcgggggggggggggggggcgcgccaggc

ggggcggggcgggggcgagggggcggggcgaggcgagaggtgcggcgggcagccaatcagagcgggcgcgctccgaaaagt
cctttatggcgaggcgggcgggcgggcgccctataaaaagcgaaagcgcgcgggcggggagtcgctgcgcgctgccttcgcccc
gtgccccgctccgcccgcgcctcgcgcggcccgccccggctctgactgaccgcgttactaaaacaggtaagtccggcctccgcgcggg
tttggcgctcccgcggcgccccctctcacggcgagcgctgccacgtcagacgaaggcgagcgagcgctctgatccttcgcc
cggacgctcaggacagcgccccgctgctcataagactcggccttagaaccagtatcagcagaaggacatttaggacgggacttgggt
gactctagggcactggtttcttccagagagcggaacaggcgaggaaaagtagtcccttctcggcgattctgcggagggatctccgtggg
gcggtgaacgccgatgatgccttactaacatgttcatgtttcttttttctacaggtcctgggtgacgaacagggtaccgccaccatggc
caccggctctcgcacaagcctgctgctggctttcggactgctgtgcctgccttggctccaggagggctccgccgctagcatcgataccgtc
gctatgtgctggaggcttgcgaaggctgtatgctgagagacttactttagatgctgcgtttggcctctgactgacgcagcatctaagtaagt
ctctcaggacacaaggcctgttactagcactcacatggaacaaatggccttagcctggaggcttgcgaaggctgtatgctgactatttcac
atactctacccgttttggcctctgactgacgggtgagagtgatgaaatagtcaggacacaaggcctgttactagcactcacatggaacaaat
ggccttagcctggaggcttgcgaaggctgtatgctgatatgaatgacaatcacagccgagttttggcctctgactgacgtggctgtgagtc
attcatatcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3' SEQ ID NO: 9 =
SEQ ID NO: 1 + SEQ ID NO: 4 5'
aatcaacctctggattacaaaatttgtgaaagattgactgggtattcttaactatgttgctccttttacgctatgtggatacgtgctttaatgcctttgt
atcatgctattgcttcccgtatggctttcatttctccttgtataaatcctgggtgctgtctctttatgaggagttgtggcccggttcaggcaac
gtggcggtgggtgctgactgtgttgcgacgcaacccccactgggtggggcattgccaccacctgtcagctcctttccgggactttcgctttccc
ctccctattgccacggcggaactcatcgccgctgccttggcgctgctggacaggggctcggctgttgggactgacaattccgtgggtg
tgtcgggggaaatcatcgtcctttccttggctgctcgctgtgttgcacctggattctgcgcggggacgtccttctgctacgtcccttcggccctc
aatccagcggaccttcttcccgcggcctgctgcggcctctcggcctcttcgcgtcttcgccttcgcctcagacgagtcggatctcccttt
gggcccctccccgcctaagcttatcgataccgtcgagatctaactgtttattgagcttataatggttacaataaagcaatagcatcaca
ttcacaataaagcattttttactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggatctcgacctcgactagagc
atggctacgtagataagtagcatggcggttaatcattaactacaaggaaccctagtgatggagttggcactccctctctgcgcgctcgt
cgctcactgaggccggcgaccaaaggctcgccgacgcccgggctttggcgggcgggcctcagtgagcgagcgagcgcgagctgg
cgtaatagcgaagaggcccgacccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgattccgttgaatggctggcgg
taatattgttctggatattaccagcaaggccgatagtttgagttcttactcaggcaagtgtattactaatcaagaagtattgcgacaac
ggttaatttgcgtgatggacagactctttactcgggtggcctcactgattataaaaacacttctcaggattctggcgtaccgttctgtctaaaatc
ccttaatcggcctcctgtttagctcccgcctctgattctaacgaggaaaagcacgttatacgtgctcgtcaaaagcaaccatagtagcgccctgt
agcggcgcatgaagcgcgggcggtgtggtgttacgcgcagcgtgaccgtacacttgccagcgccctagcgcccgctccttcgctttctt
ccctcctttctcggcacgttcgcccgtttccccgtcaagctctaaatcgggggctcccttaggggtccgatttagtgccttacggcacctcga
ccccaaaaaacttgattaggggtgatggttcacgtatgggcatcgccctgatagacggttttcggccttgacgttggagtcacgttcttta
atagtgagactctgttccaaactggaacaacactcaaccctatctcggctattctttgattataagggttttgcgatttcggcctattgggtaa
aaaatgagctgatttaacaaaaatttaacgcgaatttaacaaaaatattaacgtttacaattaaatatttgctatacaatcttctgttttggggct
tttctgattatcaaccggggtacatatgattgacatgctagttttacgattaccgttcacgtattcttctgttctcagactctcaggcaatgacct
gatagcctttgtagagaccttcaaaaatagctaccctctccggcatgaatttatcagctagaacggttgaatatcatattgatgggtgattgact
gtctccggcctttctcaccggttgaatctttactacacattactcaggcattgcatttaaaatataaggggttctaaaaattttatccttgcgttg
aaataaaggcttctcccgcaaaagtattacaggggtcataatgttttggtaacaaccgatttagctttatgctctgaggctttattgcttaatttgc
attctttgccttgcctgtatgattattggatgttgggaattcctgatgcgggtattttctccttacgcatctgtgcgggtatttcacaccgcatatggtgca
ctctcagtacaatctgctctgatccgcatagttaagccagccccgacaccgccaacaccgctgacgcgcctgacgggcttgcctgctc
ccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagagggtttaccgtcatcaccgaaacgcgcgagacgaa
agggcctcgtgatacgcctattttatagggttaatgtcatgataaatggtttcttagacgtcagggtggcactttcgggggaaatgtgcgcggaa
cccctattgttttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataattgaaaaaggaagagt
atgagtattcaacatttcgctgccttattcccttttgcggcattttgccttctgttttgcctacccagaaacgctgggtgaaagtaaaagat
gctgaagatcagttgggtgcacgagtggttcatcgaactggatctcaacagcggtaagatccttgagagttttcggcccgaaagacgtttt
ccaatgatgagcattttaaagtctgctatgtggcgcggtattatcccgtattgacggcggaagagcaactcggctcgccgcatacactatt
ctcagaatgacttgggtgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgtgccataacca
tgagtataaactgcggccaacttacttctgacaacgatcggaggaccgaaggagtaaccgctttttgcacaacatgggggatcatgta
actgccttgatcgttgggaaccggagctgaatgaagccatacacaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacg
ttgcgcaaaactattaactggcgaactacttacttagcttcccggaacaattaatagactggatggaggcgataaagtgcaggaccactt
ctgcgctcggccctccggctggctggtttattgctgataaatctggagccgggtgagcgtgggtctcgcggtatcattgcagcactggggcc

agatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggccaactatggatgaacgaaatagacagatcgtgagataggt
gcctcactgattaagcattggtaactgtcagaccaagtttactcatatatacttttagattgatttaaaacttcatttttaatttaaaaggatctaggtg
aagatcctttttgataatctcatgacaaaaatcccttaacgtgagtttctgctcactgagcgtcagaccccgtagaaaagatcaaaggatcttct
tgagatccttttttctgcgcgtaatctgctgcttgcaacaaaaaaaccaccgctaccagcgggtggtttgttgcgggatcaagagctaccaac
tcttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctg
tagcaccgcctacatacctcgtctgtctgtaacctgttaccagtggctgctgcccagtgggcgataagtcgtgtcttaccgggttgactcaagac
gatagttaccggataaaggcgcagcggctcgggctgaacgggggggttcgtgcacacagcccagcttgagcgaacgacctacaccgaact
gagatacctacagcgtgagctatgagaaagcgccacgcttcccgaaggggagaaaggcggacaggtatccggtaagcggcagggctcgg
aacaggagagcgcacgagggagcttcaggggggaaacgcctggatctttatagtcctgtcgggtttcggcacctctgacttgagcgtcgat
ttttgtgatgctcgtcagggggggcggagcctatggaaaaacgccagcaacgcggcctttttacgggttcctggccttttctggccttttctca
catgttcttctcgttatccctgattctgtggataaccgtattaccgcctttgagttagctgataccgctcggcgcagccgaacgaccgag
cgagcgcagtgagtgagcgaagcgggaagagcgcaccaatacgcgaacgcctctccccgcgcgttggccgattcattaatgcagca
gctgcgcgctcgtcgtcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgcagcga
gcgcgcagagagggagtgcccaactccatcactaggggttcctttagttaatgattaacccgccatgctacttatctacgtagccatgctct
aggacattgattattgactagtggagtccgcgttacataacttacggtaaattggcccgcctggctgaccgcccacgacccccgccattg
acgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgccacttgg
cagtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaattggcccgcctggcattatgccagtacatgacctt
atgggactttcctacttggcagtacatctacgtattagtcatcgtattaccatggctcagagtgagccccacgttctgcttcaacttccccatctc
ccccccctccccaccccccaattttgtatttttttttttaattttttgtgcagcgtatggggggcggggggggggggggggggcgcgcgcgagggc
ggggcgggggcggggcgagggggcggggcgggggcgagggcgagaggtgcggcggcagccaatcagagcggcgcgctccgaaaagt
ccttttatggcgagggcggcgggcgggcgccctataaaaaagcgaaagcgcgcggcgggcgggagtcgctgcgcgctgccttcgcccc
gtgccccgctccgcccgcgcctcgcgcggcccgcggcctctgactgaccgcgttactaaaacaggtaagtccggcctccgcgcgggg
ttttggcgctcccgcgggcgccccctcctacggcgagcgtgccacgtcagacgaagggcgcagcgcagcgtcctgatccttccgcc
cggacgctcaggacagcggcccgcgtgctcataagactcggccttagaaccacagtagtcagcagaaggacattttaggacgggacttgggt
gactctagggcactggtttttccagagagcgggaacaggcgagggaaaagtagtcccttctcggcgattctgcggagggatctccgtggg
gcggtgaacgccgatgatgcttactaaccatgttcatgttttcttttttctacaggtcctgggtgacgaacagggtaccgccaccatggc
caccggctctcgcacaagcctgctgctggctttcggactgctgtgcctgccttggctccaggagggctccgccgctagcatcgataccgtc
gctatgtgctggaggcttctgaaggctgtatgctgacaatcaacattggcagtagctcgttttggcctctgactgacgagctactgcatgttg
attgtcaggacacaaggcctgttactagcactcacatggaacaaatggccttagcctggaggcttctgaaggctgtatgctgaataagcct
ttatccatagtcccgttttggcctctgactgacgggactatggaaaggcttattcaggacacaaggcctgttactagcactcacatggaacaaa
tggcctctagcctggaggcttctgaaggctgtatgctgacaactgtctcaaattactgctcgttttggcctctgactgacgagcagtaatgag
acagttgtcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3' SEQ ID NO: 10 =
SEQ ID NO: 1 + SEQ ID NO: 55'

aatcaacctctggattacaaaatttgtgaaagattgactgggtattcttaactatgttgctccttttacgctatgtggatacgtgctttaatgcctttgt
atcatgctattgcttcccgtatggctttcattttctccttctgtataaatcctgggtgctgtctctttatgaggagttgtggcccggtgtcaggcaac
gtggcgtgggtgtgactgtgttctgacgcaacccccactgggtggggcatttgcaccacctgtcagctcctttccgggactttcgtttccc
ctccctattgccacggcggaactcatcgccgctgccttggccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgt
tgtcgggggaaatcatcgtcctttccttggctgctcgctgtgttgcacactggattctgcgcggggacgtccttctgctacgtcccttcggccctc
aatccagcggaccttcttcccgcggcctgctgcggccttctccgcgtcttcgccttcgcctcagacgagtcggatctcccttt
gggcccgcctccccgcctaagcttatcgataccgtcgagatctaactgtttattgcagcttataatggttacaaataaagcaatagcatcacaaa
tttcacaaataaagcattttttcactgcattctagtgtgtgttgcctaaactcatcaatgtatcttatcatgtctggatctcgacctcgactagagc
atggctacgtagataagtagcatggcggttaatcattaactacaaggaaacccctagtgtatggagttggccactccctctctgcgcgctcgt
cgctcactgaggccgggcgaccaaaggctgcggacgcccgggctttgcccgggcggcctcagtgagcgcagcgcgcgagctgg
cgtaatagcgaagaggccccgaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgattccgttgaatggctggcgg
taatattgttctggatattaccagcaaggccgatagtttagttcttctactcaggcaagtgtattactaatcaagaagtattgcgacaac
gggttaatttgcgtgatggacagactctttactcgggtggcctcactgattataaaaaacttctcaggattctggcgtaccgttctgtctaaaac
cctttaatcggcctcctgttttagctcccgcctgtgattctaacgaggaaaagcacgttatacgtgctcgtcaaaagcaaccatagtagcgccctgt
agcggcgcatataagcgcggcggggtgtgtgtgttacgcgcagcgtgaccgtacacttgcagcgccttagcgcggcctccttctcgtttctt
cccttcccttctcggcacgttcgcccggcttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcga
ccccaaaaaacttgattaggggtgatgggtcacgtatgggccatcgccctgatagacggtttttcgccccttgacgttggagtcacgttcttta

atagtggactcttgttccaaactggaacaacactcaaccctatctcgggtctattcttttgattataagggaatttgcggaatttcggcctattgggttaa
aaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaaatattaacgtttacaatttaaatatttgcttatacaatcttctgttttggggct
tttctgattatcaaccggggtacatatgattgacatgctagttttacgattaccgttcacgattctcttgtttgctccagactctcaggcaatgacct
gatagcctttgtagagacctctcaaaaatagctaccctctccggcatgaatttatcagctagaacgggtgaatatcatattgatggtgattgact
gtctccggcctttctcaccggttgaatctttacctacacattactcaggcattgcattaaaaatatgaggggtctaaaaattttatccttgcggtg
aaataaaggcttctcccgcaaaagtattacagggtcataatgttttggtacaaccgatttagctttatgctctgagggctttattgcttaattttgcta
attctttgccttgctgtatgatttattggatgttgggaattctgatgcgggtattttctccttacgcatctgtgcgggtatttcacaccgcatatgggtgca
ctctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgcacctgacgggcttgtctgctc
ccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggtttcaccgtcatcaccgaaacgcgcgagacgaa
agggcctcgtgatacgcctattttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaa
cccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagt
atgagtattcaacatttccgtgtcgccttattccctttttgcggcattttgccttctgttttgcctcaccagaaaacgctgggtgaaagtaaaagat
gctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagtttgcggccgaagaacgtttt
ccaatgatgagcacttttaaagtcttgctatgtggcgcggtattatcccgtattgacgcggggcaagagcaactcggctgcgcgcatacactatt
ctcagaatgacttgggtgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgtgccataacca
tgagtataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgctttttgcacaacatgggggatcatgta
actcgccttgatcgttgggaaccggagctgaatgaagccatacacaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacg
ttgcgcaactattaactggcgaactacttacttagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccactt
ctgcgctcggcccttccggctggctggtttattgctgataaatctggagccgggtgagcgtgggtctcgcggtatcattgcagcactggggcc
agatggtaagccctcccgtatcgtagtattctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggt
gcctcactgattaagcattggtaactgtcagaccaagtttactcatataacttttagattgatttaaaacttcatttttaatttaaaaggatctaggtg
aagatccttttgataatctcatgacaaaaatcccttaacgtgagtttctgctcactgagcgtcagaccccgtagaaaagatcaaggatcttct
tgagatcctttttctgcgcgtaactgtgctgttgcacaacaaaaaaaccaccgctaccagcgggtggtttgttgcgggatcaagagctaccaac
tcttttccgaaggtaactggcttcagcagagcgcagatacacaataactgtccttctagtgtagccgtagttaggccaccacttcaagaactctg
tagcaccgcctacatacctcgcctctgctaactctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccggggttgactcaagac
gatagttaccggataaaggcgcagcggctcgggctgaacgggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaact
gagatacctacagcgtgagctatgagaaagcgccacgcttcccgaaggagaaaaggcggacaggtatccggtaagcggcagggctcgg
aacaggagagcgcacgagggagcttccaggggggaaacgcctggtatctttatagtcctgtcgggtttcggcacctctgacttgagcgtcgtat
ttttgtgatgctcgtcagggggggcgagcctatggaaaaacgccagcaacgcggcctttttacgggtcctggccttttgccttttgcctca
catgttcttctcgttatccctgattctgtggataaccgtattaccgcctttgagttagctgataccgctcgcgcagccgaacgaccgag
cgagcgcagtcagtgcgaggaagcgggaagagcgcaccaatacgcacaaccgccttccccgcgcgttggccgattcattaatgcagca
gctgcgcgctcgcctcactgaggccgcccgggcaaaagcccgggcgtcgggcgacctttggctgcggcgccctcagtgagcgcgagcga
gcgcgcagagagggagtgcccaactccatcactaggggttcctttagttaatgattaacccgccatgctacttatctacgtagccatgctct
aggacattgattattgactagtggagtccgcgttacataacttacggtaaatggcccgcctggctgaccgcccacgacccccgccattg
acgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaaactgcccacttgg
cagtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaatggccgcctggcattatgccagtagatgacctt
atgggactttcctacttggcagtagatctacgtattagtcatcgtattaccatggctcaggtgagccccacgttctgcttcaacttccccatctc
ccccccctccccaccccccaatttgtatttatttttttaatttttgtgcagcgtatggggggcgggggggggggggggggcgcgccaggc
ggggcgggggcgggggcgagggggcgggggcgagggcgaggggtgcggcgagccaatcagagcggcgcgctccgaaaagttt
cctttatggcgaggcgggcgggcgggcgccctataaaaaagcgaaagcgcgcggcgggcgggagtcgctgcgcgctgccttcgcccc
gtgccccgctccgcccgcgcctcgcgcggcccgccccggctctgactgaccgcgttactaaaacaggttaagtccggcctccgcgcgggg
ttttggcgctcccgcgggcgccccctctcacggcgagcgtgccacgtcagacgaaggcgagcgcgagcgtctgatccttccgcc
cggacgctcaggacagcggcccgcgtctcataagactcggccttagaaccacagtatcagcagaaggacatttaggacgggacttgggt
gactctagggcactggttttcttccagagagcggaaacaggcgagggaaaagtagtcccttctcggcgattctgcggaggggatctccgtggg
gcgggtgaacgccgatgatgccttactaaccatgttcatgttttcttttttctacaggtcctgggtgacgaacagggtaccgccaccatggc
caccggctctcgcacaagcctgctgctggctttcgactgctgtgcctgcttggctccaggagggctccgcccgtagcatcgataccgtc
gctatgtgctggaggcttgcgaaggctgtatgctgtcactcaccttgcagagaagacgttttggcctctgactgacgtcttgcgaagggtga
gtgacaggacacaaggcctgttactagcactcacatggaacaaatggccttagcctggaggcttgcgaaggctgtatgctggttcttagc
ctatctcaagtagcgttttggcctctgactgacgctacttgagaggctaagacacaggacacaaggcctgttactagcactcacatggaaca
atggcctctagcctggaggcttgcgaaggctgtatgctggtctatgtctaaattccagcagcgttttggcctctgactgacgctgctggaata

gacatgacacaggacaaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3' SEQ ID NO: 11
= SEQ ID NO: 1 + SEQ ID NO: 65'

aatcaacctctggattacaaaatttgtgaaagattgactgggtattcttaactatgttgctccttttacgctatgtggatacgtgctttaatgcctttgt
atcatgctattgcttcccgatggctttcattttctcctccttgataaaatcctgggtgctgtctctttatgaggagttgtggcccggtgtcaggcaac
gtggcgtgggtgtgactgtttgtgacgcaacccccactgggtggggcattgccaccacctgtcagctcctttccgggactttcgctttccc
cctccctattgccacggcggaactcatcgccgcctgccttgcccgcgtgctggacaggggctcggctgttgggcactgacaattccgtgggtg
tgtcgggggaaatcatcgctctttccttggctgctcgctgtgttgcacctggattctgcgcgggacgtccttctgctacgtcccttcggccctc
aatccagcggaccttcttcccgcggcctgctgccggcctctgcggcctcttccgcgtcttcgccttcgcctcagacgagtcggatctcccttt
gggcccgcctccccgcctaagcttatcgataccgtcgagatctaacttgtttattgcagcttataatggttacaataaagcaatagcatcaciaa
tttcaciaataaagcatttttttactgcatctagttgtgggttgcctaaactcatcaatgtatcttatcatgtctggatctcgacctcgactagagc
atggctacgtagataagtagcatggcgggtaatcattaactacaaggaacccctagtgtatggagttggccactccctctctgcgcgctcgt
cgctcactgaggccgggaccaaaggctgcccgcacgcccgggctttgcccgggaggcctcagtgaagcagcgagcgagcgagcgtgg
cgtaatagcgaagaggcccgacccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggcgattccggtgcaatggctggcg
taatattgttctggatattaccagcaaggccgatagtttgagttcttctactcaggcaagtgtattactaatcaagaagtattgcgacaac
gggtaatttgcgtgatggacagactcttttactcgggtggcctcactgattataaaaacacttctcaggattctggcgtagcgttctgtctaaaac
ccttaatcggcctcctgttttagctcccgcctgtattctaacgaggaaaacacgttatacgtgctcgtcaaagcaaccatagtagcgccctgt
agcggcgcatgaagcgcggcggtgtgggtgttacgcgcagcgtgaccgctacacttgccagcgccctagcgccccgctcctttcgctttctt
cccttctttctcgccacgttcgcggcgtttccccgtaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcga
ccccaaaaaacttgattaggggtgatgggtcacgtatgggccatcgccctgatagacgggttttcgccctttgacgttggagtcacgttctta
atagtggaactctgttccaaactggaacaacactcaaccctatctcggctctattcttttgattataagggttttgcgatttcggcctatttggtta
aaaatgagctgatttaacaaaaatttaacgcgaatttaacaaaaatattaacgtttacaatttaaatatttgctatacaatcttctgttttggggct
tttctgattatcaaccggggtacatatgattgacatgctagttttacgattaccggtcatcgattctctgtttgtctccagactctcaggcaatgacct
gatagcctttgtagagacctctcaaaaatagctaccctctccggcatgaatttatcagctagaacggttgaatatcatattgatgggtgattgact
gtctccggcctttctcacccgttgaatctttacctacacattactcaggcattgcattaaaaatatagagggttctaaaaattttatccttgcttg
aaataaaggcttctcccgcaaaagtattacaggggtcataatgttttggtaacaaccgatttagctttatgctctgaggcttattgcttaatttgc
attctttgccttgctgtatgatttattggatgttgaattctgatgcgggtattttctccttacgcatctgtgcgggtatttcacaccgcatatgggtga
ctctcagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgcctgacgggcttctgctc
ccggcatccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagagggtttaccgctcatcaccgaaacgcgcgagacgaa
agggcctcgtgatacgcctattttataggttaatgtcatgataataatggttcttagacgtcaggtggcacttttcgggggaaatgtgcgcggaa
cccctatttgtttatttttctaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaagggaaggt
atgagtattcaacatttccgtgtcgccttattccctttttgcggcattttgccttctgttttgcctaccagaaaacgctgggtgaaagtaaaagat
gctgaagatcagttgggtgcacgagtggttacctgaactggatctcaacagcggtaagatccttgagagtttccgccccgaagaacgtttt
ccaatgatgagcacttttaaaagtctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactatt
ctcagaatgacttgggtgagtactaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataacca
tgagtataactgacgccaacttactctgacaacgatcggaggaccgaaggagctaaccgctttttgcacaacatgggggatcatgta
actgccttgatcgttgggaaccggagctgaatgaagccatacacaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacg
ttgcgcaactattaactggcgaactacttacttagcttcccggcaacaattaatagactggatggaggcggataaaagtgcaggaccactt
ctgcgctcggcccttccggctggctgtttattgtgataaatctggagccgggtgagcgtgggtctcgcggtatcattgcagcactggggcc
agatggtaagccctcccgtatcgtatgtatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggt
gcctcactgattaagcattggtaactgtcagaccaagttaactcatatatacttttagattgatttaaaacttcatttttaatttaaaaggatctaggtg
aagatccttttgataatctcatgacaaaaatcccttaacgtgagtttccgttccactgagcgtcagacccccgtagaaaagatcaaaaggatcttct
tgagatccttttttctgcgcgtaatctgctgcttgcaacaaaaaaaccaccgctaccagcgggtgggttgggttccggatcaagagctaccaac
tcttttccgaaggtaactggcttcagcagagcgcagatacacaataactgtccttctagtgtagccgtaggttaggccaccacttcaagaactctg
tagcaccgcctacatacctcgtctgctaactctgttaccagtggctgctgccagtgggcgataagtcgtgtcttaccgggttgactcaagac
gatagttaccggataaaggcgcagcggctgggctgaacgggggggttctgtcacacagcccagcttggagcgaacgacctacaccgaact
gagatacctacagcgtgagctatgagaaagcgcacgcttcccgaaggagaaaggcggacaggtatccggtaagcggcagggtcgg
aacaggagagcgcacgaggagcttccaggggggaaacgcctggatctttatagtcctgtcgggtttccacactctgacttgagcgtcgat
ttttgtgatgctcgtcagggggggcgagcctatggaaaaacgccagcaacgcggcctttttacgggtcctggccttttctggccttttgc
catgttcttctcgttattcccctgattctgtggataaccgtattaccgcctttgagtgagctgataaccgctcgccgcagccgaacgaccgag
cgagcgagtcagtgagcgaggaagcggaagagcgcccaatacgcacacccgcttccccgcggttggccgattcattaatgcagca

gctgcgcgctcgcctcactgaggccgcccggggcaaaagcccgggctcgggcgacctttggtcgcccggcctcagtgagcgagcga
gcgcgcagagagggagtgcccaactccatcactaggggttccttgtagttaatgattaacccgccatgctacttatctacgtagccatgctct
aggacattgattattgactagtggaggttcgcgttacataacttacggtaaattggcccgcctggctgaccgcccacgacccccgccattg
acgtcaataatgacgtatgttcccatagtaacgccaatagggaactttccattgacgtcaatgggtggagttttacggtaaactgccacttgg
cagtacatcaagtgtatcatatgccaaagtacgccccctattgacgtcaatgacggtaaattggcccgcctggcattatgccagtacatgacctt
atgggactttcctacttggcagtacatctacgtattagtcacgctattaccatggctcgaggtgagccccacgttctgcttcaactctccccatctc
ccccccctccccaccccccaattttgtattatttttttaatttttgtgcagcgatggggggcgggggggggggggggcgcgcgccaggc
ggggcgggggcgggggcgagggggcgggggcgggggcgagggcgagaggtgcggcgggcagccaatcagagcgggcgcgctccgaaagt
ccttttatggcgagggcgggcgggcgggcgggccctataaaaaagcgaagcgcgcgggcgggggagtcgctgcgcgctgccttcgcccc
gtgccccgctccgcccgcctcgcgcggcccgccccggctctgactgaccgcttactaaaacaggtaagtccggcctccgcgcggg
tttggcgctcccgcggcgccccctctcacggcgagcgctgccacgtcagacgaaggcgagcgagcgctctgatccttcgcc
cggacgctcaggacagcgccccgctgctcataagactcggccttagaaccacagtatcagcagaaggacatttttaggacgggacttgggt
gactctagggcactggttttcttccagagagcggaacaggcgaggaaaagtagtcccttctcggcgattctgcggagggatctccgtggg
gcgggtgaacgccgatgatgccttactaaccatgttcatgtttctttttttctacaggctcctgggtgacgaacagggtaccgccaccatggc
caccggctctcgcacaagcctgctgctggctttcggactgctgtgccttgctccaggagggctccgccgctagcatcgataccgctc
gctatgtgctggaggctgctgaaggctgtatgctgctcactgaattgcttaccgctccgcttttggcctctgactgacggagcggtgaagattca
agttagcaggacacaaggcctgttactagcactcacatggaacaaatggcctctagcctggaggcttgctgaaggctgtatgctgtgctga
tcctatctcaagtagcgttttggcctctgactgacgctacttgagaggctaagacacaggacacaaggcctgttactagcactcacatggaac
aaatggcctctagcctggaggcttgctgaaggctgtatgctgtatgttccgggaaacagtgactgcttttggcctctgactgacgattcactgt
cccggaaacatcaggacacaaggcctgttactagcactcacatggaacaaatggcctctctagaat 3'

[0054] As will be appreciated by those skilled in the art, because the recombinant plasmid is a circular vector, the one or more sequences of the miRNA expression cassettes may be connected at the 3' end of SEQ ID NO. 1, as shown in SEQ ID NO. 7-11 or at the 5' end of SEQ ID NO. 1.

[0055] As will be appreciated by those skilled in the art, a perfect match of nucleotides with each of the miRNA expression cassette sequences is not necessary in order to have the desired result of decreased bioavailability of the target biomolecule as a result of the target cell producing the miRNA sequence that will bind to and degrade the mRNA of the target biomolecule. In some embodiments of the present disclosure, about 80% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result. In some embodiments of the present disclosure, about 85% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result. In some embodiments of the present disclosure, about 90% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result. In some embodiments of the present disclosure, about 95% to about 100% nucleotide sequence matching with each of the miRNA expression cassettes causes the desired result.

Example 1

Expression Cassette

[0056] Expression cassettes for expressing miRNA were synthesized. The synthesized miRNA expression cassettes were cloned into the pAVA-00200 plasmid backbone containing the CASI promoter, multiple cloning site (MCS), Woodchuck Hepatitis Virus post-transcriptional regulatory element (WPRE), and Simian virus 40 (SV40) polyadenylation (polyA) sequence, all flanked by the AAV2 inverted terminal repeats (ITR). pAVA-00200 was cut with the restriction enzymes KpnI and XbaI in the MCS and separated on a 1% agarose gel. The band of interest was excised and purified using a gel extraction kit. Each miRNA expression cassette was amplified by polymerase chain reaction (PCR) using Taq polymerase and the PCR products were gel purified and the bands on interest were also excised and purified using a gel extraction kit. These PCR products contained the miRNA expression cassettes in addition to 15 base pair 5' and 3' overhangs that aligned with the ends of the linearized pAVA-00200 backbone. Using in-fusion cloning, the amplified miRNA expression cassettes are integrated with the pAVA-00200 backbone via homologous recombination.

The resulting RP contained the following: 5' ITR, CASI promoter, miRNA expression cassette, WPRE, SV40 polyA and ITR 3'.

Claims

1. A composition that comprises a recombinant plasmid (RP) that comprises a sequence of nucleotides that is 95-100% identical to the full length of SEQ ID NO: 11.
 2. The composition of claim 1, wherein the RP is encased in a protein coat, a lipid vesicle, or any combination thereof.
 3. The composition of claim 1, wherein the RP is encased in a viral vector.
 4. The composition of claim 3, wherein the viral vector is one of a double stranded DNA virus, a single stranded DNA virus, a single stranded RNA virus, or a double stranded RNA virus.
 5. The composition of claim 3, wherein the viral vector is an adeno-associated virus.
-